Table 1 Characteristics of the discovery and replication cohorts

From: Nasal DNA methylation at three CpG sites predicts childhood allergic disease

 

PIAMA (Discovery)

EVA-PR (Replication)

COPSAC2010 (Replication)

MAKI (Replication)

Sample size

348

481

503

259

Age (years)

16.3 (0.20)

15.5 (3.0)

6.0 (0.2)

5.8 (0.4)

Gender male

179/348 (51.4%)

248/481 (51.6%)

217/503 (43.1%)

146/259 (56.4%)

Smoking *

37/297 (12.5%)

NA

35/ 503 (6.9%)

15/259 (5.8%)

Asthma

23/348 (6.6%)

236/481 (48.9%)

31/503 (6.2%)

20/255 (7.8%)

Rhinitis

59/348 (17.0%)

295/481 (61.3%)

60/503 (53.3%)

27/259(10.4%)

Eczema

29/348 (8.3%)

89/481 (18.5%)

55/503 (10.8%)

28/259 (10.8%)

Positive allergen-specific IgE

162/348 (46.6%)

311/481 (64.7%)

85/503 (18.7%)

56/ 205 (27.3%)

Allergy

67/348 (19.3%)

267/481 (55.5%)

37/503 (8.9%)

29/259 (11.2%)

  1. Continuous variables are presented as mean (SD); categorical variables are presented as (number of “yes”)/(total number (with this phenotype available)) (percentage).
  2. PIAMA prevention and incidence of asthma and mite allergy birth cohort (Netherlands), EVA-PR epigenetic variation and childhood asthma in Puerto Ricans (USA), COPSAC2010 Copenhagen prospective study on asthma in childhood (Denmark), MAKI trial (the Netherlands).
  3. *Smoking in COPSAC2010 and MAKI cohort refers to second-hand smoking.